• Register
  • Login

European Journal of Molecular & Clinical Medicine

  1. Home
  2. Comparison between Dydrogesterone and micronized Progesterone on threatened abortion- A Prospective Observational Study

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Comparison between Dydrogesterone and micronized Progesterone on threatened abortion- A Prospective Observational Study

    Author

    • Pooja Patil, Shesha Sinha
,

Document Type : Research Article

  • Article Information
  • Download
  • Export Citation
  • Statistics
  • Share

Abstract

Threatened abortion is defined as “pregnancy-related bloody vaginal discharge or frank bleeding without cervical dilatation during the first half of pregnancy. Progesterone also called ‘pregnancy hormone’ is prescribed among pregnant women with threatened abortion as it plays a critical role in the maintenance of pregnancy.  AIM: This study aimed at comparing the clinical effectiveness of dydrogesterone and micronized Progesterone in continuing pregnancy among pregnant women diagnosed with threatened abortion. Material and Methods: This was a single Centre, hospital-based, prospective observational study conducted at LN Medical College, Bhopal, for a duration of 24 months. The present study enrolled a total of 143 pregnant women: 97 women with threatened abortion were given 40 mg Dydrogesterone stat followed by 20-30mg daily, continued for one week after stopping bleeding and 46 women were given micronized Progesterone 400 mg per day vaginally, continued until the end of vaginal bleeding. Results:  Bleeding stopped in significantly higher proportions of patients of the dydrogesterone group (80.4%) as compared to 65.2% cases of micronized progesterone group (p= 0.032). The mean duration of bleeding after giving the drug in the dydrogesterone group was 3.58 (±1.44) days in comparison to micronized progesterone group it was 4.48(±1.60) days. Continuation of pregnancy 15 days after the initiation of bleeding was found in 80.4% of cases in the dydrogesterone group as compared to micronized progesterone group (67.4%) (p= 0.072). Dizziness and Bloating were noted in 10.33% and 7.2% cases respectively in the dydrogesterone group. Whereas dizziness, headache and breast heaviness were noted in 10.9%, 2.2% and 2.2% cases respectively in micronized progesterone group. The observed difference in side effects between the two groups was statistically insignificant (p>0.05).  Conclusion: Both dydrogesterone group and micronized progesterone are effective in threatened abortion. Dydrogesterone has lesser side effects when compared to natural micronized progesterone.

  • XML
  • PDF 335.42 K
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
    • Article View: 17
    • PDF Download: 50
European Journal of Molecular & Clinical Medicine
Volume 10, Issue 2 - Issue Serial Number 2
January 2023
Page 2519-2527
Files
  • XML
  • PDF 335.42 K
Share
Export Citation
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
Statistics
  • Article View: 17
  • PDF Download: 50

APA

Shesha Sinha, P. P. (2023). Comparison between Dydrogesterone and micronized Progesterone on threatened abortion- A Prospective Observational Study. European Journal of Molecular & Clinical Medicine, 10(2), 2519-2527.

MLA

Pooja Patil, Shesha Sinha. "Comparison between Dydrogesterone and micronized Progesterone on threatened abortion- A Prospective Observational Study". European Journal of Molecular & Clinical Medicine, 10, 2, 2023, 2519-2527.

HARVARD

Shesha Sinha, P. P. (2023). 'Comparison between Dydrogesterone and micronized Progesterone on threatened abortion- A Prospective Observational Study', European Journal of Molecular & Clinical Medicine, 10(2), pp. 2519-2527.

VANCOUVER

Shesha Sinha, P. P. Comparison between Dydrogesterone and micronized Progesterone on threatened abortion- A Prospective Observational Study. European Journal of Molecular & Clinical Medicine, 2023; 10(2): 2519-2527.

  • Home
  • About Journal
  • Editorial Board
  • Submit Manuscript
  • Contact Us
  • Glossary
  • Sitemap

News

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

Newsletter Subscription

Subscribe to the journal newsletter and receive the latest news and updates

© Journal Management System. Powered by ejournalplus